Abstract
Abstract Many antiseizure medications (ASMs) are associated with hematological toxicity. A wide spectrum of hematological abnormalities can be seen after prescribing an ASM, ranging from mild thrombocytopenia or neutropenia to anemia, red cell aplasia, or even bone marrow failure. The magnitude of the problem is illustrated by the fact that at least one hematological abnormality was noted in 33% of patients taking valproate in one study. Fortunately, potentially fatal hematological disorders are rare; for example, aplastic anemia has an incidence of only a few cases per million per year. Nonetheless, knowledge of the hematological adverse effects of these drugs is crucial when selecting ASMs in patients with epilepsy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
